See more : Prestige Estates Projects Limited (PRESTIGE.NS) Income Statement Analysis – Financial Results
Complete financial analysis of ERYTECH Pharma S.A. (ERYP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ERYTECH Pharma S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- GD Entertainment & Technology, Inc. (GDET) Income Statement Analysis – Financial Results
- ARA LOGOS Logistics Trust (K2LU.SI) Income Statement Analysis – Financial Results
- GEPIC Energy Development Co., Ltd. (000791.SZ) Income Statement Analysis – Financial Results
- Vikas Proppant & Granite Limited (VIKASPROP.BO) Income Statement Analysis – Financial Results
- Hubei Guangji Pharmaceutical Co., Ltd. (000952.SZ) Income Statement Analysis – Financial Results
ERYTECH Pharma S.A. (ERYP)
About ERYTECH Pharma S.A.
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 3.36M | 4.14M | 3.36M | 19.72M | 10.78M | 6.61M | 1.80M | 3.46M |
| Cost of Revenue | 0.00 | 0.00 | 57.58M | 52.19M | 33.47M | 25.46M | 19.72M | 10.78M | 6.61M | 5.33M | 3.46M |
| Gross Profit | 0.00 | 0.00 | -57.58M | -48.83M | -29.33M | -22.10M | 0.00 | 0.00 | 0.00 | -3.53M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -1,451.52% | -708.80% | -656.90% | 0.00% | 0.00% | 0.00% | -195.63% | 0.00% |
| Research & Development | 19.91M | 45.10M | 57.58M | 52.19M | -19.72M | -25.46M | 0.00 | 0.00 | 0.00 | 2.50M | 0.00 |
| General & Administrative | 13.89M | 15.10M | 14.97M | 17.16M | 14.60M | 8.52M | 6.66M | 7.62M | 4.36M | 3.55M | 3.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.89M | 15.10M | 14.97M | 17.16M | 14.60M | 8.52M | 6.66M | 7.62M | 4.36M | 3.55M | 3.30M |
| Other Expenses | -6.65M | -3.69M | -3.72M | -5.28M | -4.45M | -3.10M | -3.99M | -2.81M | -2.03M | -4.29M | -5.68M |
| Operating Expenses | 27.15M | 56.52M | 68.83M | 64.07M | 10.15M | 5.43M | 2.67M | 4.81M | 2.34M | 1.76M | -2.39M |
| Cost & Expenses | 27.15M | 56.52M | 68.83M | 64.07M | 43.62M | 30.89M | 22.39M | 15.58M | 8.95M | 7.09M | 1.07M |
| Interest Income | 4.45M | 13.00K | 889.00K | 2.95M | 163.00K | 405.00K | 545.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.36M | 2.14M | 5.35M | 1.53M | 9.00K | 15.00K | 4.00K | 5.00K | 6.80K | 4.66K | 9.38K |
| Depreciation & Amortization | -19.90M | 9.06M | 889.00K | 2.95M | 797.00K | 532.00K | 425.00K | 288.00K | 276.52K | 180.30K | 292.09K |
| EBITDA | -22.69M | -47.46M | -67.94M | 5.28M | 4.45M | 3.36M | -21.47M | -14.72M | -8.60M | -8.00M | -1.86M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,817.09% | -904.20% | -980.56% | -108.90% | -136.63% | -130.00% | -443.87% | -53.83% |
| Operating Income | -2.80M | -56.52M | -68.83M | -64.07M | -43.62M | -30.89M | -22.39M | -15.58M | -8.95M | -7.09M | -1.07M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,904.70% | -1,054.16% | -918.22% | -113.55% | -144.61% | -135.32% | -393.13% | -31.04% |
| Total Other Income/Expenses | 3.09M | 2.72M | -4.47M | -67.94M | -42.67M | -2.64M | 488.00K | 567.00K | 68.17K | -1.10M | -1.09M |
| Income Before Tax | 293.00K | -53.80M | -73.30M | -62.66M | -38.22M | -33.53M | -21.90M | -15.02M | -8.88M | -8.18M | -2.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -1,862.66% | -923.68% | -996.82% | -111.07% | -139.35% | -134.29% | -454.14% | -62.54% |
| Income Tax Expense | 521.00K | 2.00K | 3.00K | -1.00K | 2.00K | -3.00K | 10.00K | -3.00K | -20.16K | -40.02K | 7.64K |
| Net Income | -228.00K | -53.80M | -73.30M | -62.66M | -38.22M | -33.53M | -21.91M | -15.01M | -8.86M | -8.14M | -2.17M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -1,862.63% | -923.73% | -996.73% | -111.13% | -139.32% | -133.98% | -451.92% | -62.77% |
| EPS | -0.01 | -2.27 | -3.99 | -3.49 | -2.13 | -1.87 | -2.74 | -2.16 | -1.51 | -1.74 | -0.39 |
| EPS Diluted | -0.01 | -2.27 | -3.99 | -3.49 | -2.13 | -1.87 | -2.74 | -2.16 | -1.51 | -1.74 | -0.39 |
| Weighted Avg Shares Out | 31.02M | 23.69M | 18.39M | 17.94M | 17.94M | 17.94M | 7.98M | 6.96M | 5.87M | 4.69M | 5.54M |
| Weighted Avg Shares Out (Dil) | 31.02M | 23.69M | 18.39M | 17.94M | 17.94M | 17.94M | 7.98M | 6.96M | 5.87M | 4.69M | 5.54M |
ERYTECH Reports Financial Highlights for Q4 2015
ERYTECH to host a webcast on September 29, 2015 for its 2015 half-year results
ERYTECH provides business update and financial results for the full year 2014
Source: https://incomestatements.info
Category: Stock Reports